As per the agreement, MPP will further license non-exclusive sub-licences to manufacturers and diversify the manufacturing base for the supply of quality-assured or World Health Organization (WHO) -prequalified molnupiravir to countries covered by the MPP Licence.
from The Financial Express https://ift.tt/3BgO42w
Thursday, 28 October 2021
MSD, MPP ink voluntary licencing agreement towards access of Covid-19 medicine molnupiravir to LMI countries
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment